Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.80
ALKS's Cash to Debt is ranked lower than
72% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 49.71 vs. ALKS: 1.80 )
Ranked among companies with meaningful Cash to Debt only.
ALKS' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: 1.53 Max: No Debt
Current: 1.8
Equity to Asset 0.71
ALKS's Equity to Asset is ranked higher than
53% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ALKS: 0.71 )
Ranked among companies with meaningful Equity to Asset only.
ALKS' s Equity to Asset Range Over the Past 10 Years
Min: -0.15  Med: 0.61 Max: 0.9
Current: 0.71
-0.15
0.9
F-Score: 3
Z-Score: 6.81
M-Score: -3.12
WACC vs ROIC
15.69%
-27.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -43.90
ALKS's Operating margin (%) is ranked higher than
56% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -73.78 vs. ALKS: -43.90 )
Ranked among companies with meaningful Operating margin (%) only.
ALKS' s Operating margin (%) Range Over the Past 10 Years
Min: -35.7  Med: -7.62 Max: 41.29
Current: -43.9
-35.7
41.29
Net-margin (%) -43.91
ALKS's Net-margin (%) is ranked higher than
55% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -75.29 vs. ALKS: -43.91 )
Ranked among companies with meaningful Net-margin (%) only.
ALKS' s Net-margin (%) Range Over the Past 10 Years
Min: -36.15  Med: -1.29 Max: 69.37
Current: -43.91
-36.15
69.37
ROE (%) -20.24
ALKS's ROE (%) is ranked higher than
59% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -32.24 vs. ALKS: -20.24 )
Ranked among companies with meaningful ROE (%) only.
ALKS' s ROE (%) Range Over the Past 10 Years
Min: -18.25  Med: 0.11 Max: 65.64
Current: -20.24
-18.25
65.64
ROA (%) -14.62
ALKS's ROA (%) is ranked higher than
63% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. ALKS: -14.62 )
Ranked among companies with meaningful ROA (%) only.
ALKS' s ROA (%) Range Over the Past 10 Years
Min: -12.04  Med: -0.42 Max: 27.26
Current: -14.62
-12.04
27.26
ROC (Joel Greenblatt) (%) -74.82
ALKS's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. ALKS: -74.82 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALKS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -60.91  Med: 6.41 Max: 131.93
Current: -74.82
-60.91
131.93
Revenue Growth (3Y)(%) 7.40
ALKS's Revenue Growth (3Y)(%) is ranked higher than
57% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. ALKS: 7.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALKS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -22.1  Med: 10.10 Max: 69.6
Current: 7.4
-22.1
69.6
EPS Growth (3Y)(%) 15.40
ALKS's EPS Growth (3Y)(%) is ranked higher than
73% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. ALKS: 15.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALKS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -24.2  Med: 19.10 Max: 226.4
Current: 15.4
-24.2
226.4
» ALKS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ALKS Guru Trades in Q2 2015

Jim Simons 229,286 sh (+15.40%)
Pioneer Investments 287,959 sh (+14.19%)
Ken Fisher 107,164 sh (unchged)
Vanguard Health Care Fund 6,229,583 sh (unchged)
Murray Stahl 25,000 sh (unchged)
Jeff Auxier 26,851 sh (-0.37%)
» More
Q3 2015

ALKS Guru Trades in Q3 2015

George Soros 7,900 sh (New)
Ken Fisher 119,920 sh (+11.90%)
Vanguard Health Care Fund 6,879,583 sh (+10.43%)
Pioneer Investments 300,413 sh (+4.32%)
Jeff Auxier 26,851 sh (unchged)
Murray Stahl 25,000 sh (unchged)
Jim Simons Sold Out
» More
Q4 2015

ALKS Guru Trades in Q4 2015

Paul Tudor Jones 6,782 sh (New)
Jim Simons 26,286 sh (New)
Ken Fisher 120,327 sh (+0.34%)
Murray Stahl 25,000 sh (unchged)
Jeff Auxier 26,851 sh (unchged)
Vanguard Health Care Fund 6,851,996 sh (-0.40%)
Pioneer Investments 208,726 sh (-30.52%)
George Soros 3,400 sh (-56.96%)
» More
Q1 2016

ALKS Guru Trades in Q1 2016

Paul Tudor Jones 21,964 sh (+223.86%)
Pioneer Investments 345,537 sh (+65.55%)
Vanguard Health Care Fund 8,603,676 sh (+25.56%)
Murray Stahl 25,000 sh (unchged)
Jim Simons Sold Out
George Soros Sold Out
Ken Fisher 120,297 sh (-0.02%)
Jeff Auxier 26,751 sh (-0.37%)
» More
» Details

Insider Trades

Latest Guru Trades with ALKS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:DYAX, NAS:SGEN, NAS:OPK, OTCPK:SBMFF, NAS:ALNY, NAS:UTHR, NAS:ANAC, NAS:JAZZ, NAS:JUNO, NAS:TECH, OTCPK:BTGGF, NAS:ACAD, NAS:ICPT, NAS:MDVN, OTCPK:GMXAY, OTCPK:LBTSF, NYSE:XON, NAS:CBPO, NAS:IONS, OTCPK:SOLTF » details
Traded in other countries:8AK.Germany,
Alkermes PLC is a biotechnology company engaged in developing, manufacturing & commercializing medicines. The Company has a portfolio of commercial drug products & a clinical pipeline of product candidates that address central nervous system disorders.

Alkermes PLC is a biotechnology incorporated on May 4, 2011. The Company is engaged in developing, manufacturing and commercializing medicines to address unmet medical needs of patients in various therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders such as schizophrenia, depression, addiction and multiple sclerosis. The company is subject to the laws and regulations from the U.S. Foreign Corrupt Practices Act (FCPA).

Ratios

vs
industry
vs
history
P/B 5.05
ALKS's P/B is ranked lower than
67% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 3.34 vs. ALKS: 5.05 )
Ranked among companies with meaningful P/B only.
ALKS' s P/B Range Over the Past 10 Years
Min: 1.66  Med: 4.26 Max: 412.83
Current: 5.05
1.66
412.83
P/S 10.19
ALKS's P/S is ranked higher than
54% of the 799 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. ALKS: 10.19 )
Ranked among companies with meaningful P/S only.
ALKS' s P/S Range Over the Past 10 Years
Min: 2.21  Med: 7.05 Max: 18.81
Current: 10.19
2.21
18.81
EV-to-EBIT -23.71
ALKS's EV-to-EBIT is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 21.76 vs. ALKS: -23.71 )
Ranked among companies with meaningful EV-to-EBIT only.
ALKS' s EV-to-EBIT Range Over the Past 10 Years
Min: -17302.9  Med: -19.80 Max: 1284.7
Current: -23.71
-17302.9
1284.7
EV-to-EBITDA -35.59
ALKS's EV-to-EBITDA is ranked lower than
99.99% of the 305 Companies
in the Global Biotechnology industry.

( Industry Median: 18.58 vs. ALKS: -35.59 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALKS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1362.6  Med: 6.20 Max: 262.1
Current: -35.59
-1362.6
262.1
Current Ratio 3.74
ALKS's Current Ratio is ranked lower than
57% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ALKS: 3.74 )
Ranked among companies with meaningful Current Ratio only.
ALKS' s Current Ratio Range Over the Past 10 Years
Min: 2.01  Med: 6.22 Max: 15.4
Current: 3.74
2.01
15.4
Quick Ratio 3.54
ALKS's Quick Ratio is ranked lower than
55% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. ALKS: 3.54 )
Ranked among companies with meaningful Quick Ratio only.
ALKS' s Quick Ratio Range Over the Past 10 Years
Min: 1.95  Med: 5.99 Max: 15.4
Current: 3.54
1.95
15.4
Days Inventory 119.79
ALKS's Days Inventory is ranked higher than
53% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.52 vs. ALKS: 119.79 )
Ranked among companies with meaningful Days Inventory only.
ALKS' s Days Inventory Range Over the Past 10 Years
Min: 86.09  Med: 110.47 Max: 166.33
Current: 119.79
86.09
166.33
Days Sales Outstanding 81.80
ALKS's Days Sales Outstanding is ranked lower than
62% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 63.07 vs. ALKS: 81.80 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALKS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.46  Med: 82.14 Max: 90.32
Current: 81.8
27.46
90.32
Days Payable 95.08
ALKS's Days Payable is ranked higher than
64% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 60.55 vs. ALKS: 95.08 )
Ranked among companies with meaningful Days Payable only.
ALKS' s Days Payable Range Over the Past 10 Years
Min: 39.15  Med: 65.98 Max: 561.6
Current: 95.08
39.15
561.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 67.11
ALKS's Price/Net Cash is ranked lower than
95% of the 691 Companies
in the Global Biotechnology industry.

( Industry Median: 4.99 vs. ALKS: 67.11 )
Ranked among companies with meaningful Price/Net Cash only.
ALKS' s Price/Net Cash Range Over the Past 10 Years
Min: 3.39  Med: 12.40 Max: 115.47
Current: 67.11
3.39
115.47
Price/Net Current Asset Value 20.73
ALKS's Price/Net Current Asset Value is ranked lower than
87% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. ALKS: 20.73 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALKS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.39  Med: 11.24 Max: 343
Current: 20.73
2.39
343
Price/Tangible Book 7.90
ALKS's Price/Tangible Book is ranked lower than
74% of the 945 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. ALKS: 7.90 )
Ranked among companies with meaningful Price/Tangible Book only.
ALKS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.8  Med: 9.69 Max: 365.22
Current: 7.9
1.8
365.22
Price/Projected FCF 6.92
ALKS's Price/Projected FCF is ranked lower than
69% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 3.56 vs. ALKS: 6.92 )
Ranked among companies with meaningful Price/Projected FCF only.
ALKS' s Price/Projected FCF Range Over the Past 10 Years
Min: 2  Med: 3.87 Max: 20.95
Current: 6.92
2
20.95
Price/Median PS Value 1.44
ALKS's Price/Median PS Value is ranked lower than
73% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. ALKS: 1.44 )
Ranked among companies with meaningful Price/Median PS Value only.
ALKS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.42  Med: 1.69 Max: 14.36
Current: 1.44
0.42
14.36
Earnings Yield (Greenblatt) (%) -4.26
ALKS's Earnings Yield (Greenblatt) (%) is ranked higher than
63% of the 1100 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. ALKS: -4.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALKS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -4.26  Med: 2.35 Max: 53.4
Current: -4.26
-4.26
53.4

More Statistics

Revenue (TTM) (Mil) $623.9
EPS (TTM) $ -1.82
Beta2.05
Short Percentage of Float6.63%
52-Week Range $27.14 - 80.71
Shares Outstanding (Mil)151.17

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 710 837 987
EPS ($) -0.30 0.30 0.50
EPS w/o NRI ($) -0.30 0.30 0.50
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for NAS:ALKS

Headlines

Articles On GuruFocus.com
AvalonBay Communities, Equinix, Jarden, Alkermes Approach 52-Week Highs Jan 04 2016 
Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 
Weekly CEO Sells Highlight: Herbalife, CNO Financial Group, Alkermes plc, and TransDigm Oct 08 2011 
Alkermes Inc. Reports Operating Results (10-Q) Feb 03 2011 
Weekly Guru Bargains Highlights: SKX, VRX, ALKS, DF, SVU Dec 05 2010 
Alkermes Inc. Reports Operating Results (10-Q) Nov 04 2010 
Alkermes Inc. Reports Operating Results (10-K) May 21 2010 
Alkermes Inc. Reports Operating Results (10-Q) Feb 04 2010 
Opportunistic Coat-tailing Jan 05 2010 
Weekly Guru Bargains Highlights: Coinstar Inc, Fair Isaac Corp, Alkermes Inc, American International Dec 12 2009 

More From Other Websites
Alkermes Plc – Value Analysis (NASDAQ:ALKS) : June 21, 2016 Jun 21 2016
Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : June 20, 2016 Jun 20 2016
ALKERMES PLC. Files SEC form 8-K, Other Events Jun 08 2016
ETF’s with exposure to Alkermes Plc : June 8, 2016 Jun 08 2016
ALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers Jun 02 2016
Alkermes’ Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare... Jun 01 2016
Alkermes Rises on Evercore’s ‘Buy’ Rating, Buying Support Jun 01 2016
Alkermes’ Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare... Jun 01 2016
Alkermes’ Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare... Jun 01 2016
Alkermes Plc Conference Call to Discuss Data and Study Design from FORWARD-3 and FORWARD-4 Studies... Jun 01 2016
ALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters... May 26 2016
Alkermes Begins Phase I Study on Immuno-Oncology Drug May 26 2016
Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors May 26 2016
Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors May 26 2016
Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors May 26 2016
Alkermes Initiates Phase 1 Clinical Trial Of Immuno-Oncology Drug Candidate ALKS 4230 May 25 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230 May 25 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230 May 25 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230 May 25 2016
ETF’s with exposure to Alkermes Plc : May 24, 2016 May 24 2016
Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology... May 24 2016
Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology... May 24 2016
Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology... May 24 2016
ALKERMES PLC. Financials May 04 2016
FDA Warns of Rare Impulse Reactions to Abilify Medication May 04 2016
FDA Warns of Rare Reactions to Abilify Medication May 03 2016
Alkermes Plc :ALKS-US: Earnings Analysis: Q1, 2016 By the Numbers May 03 2016
Alkermes (ALKS) Reports Narrower-than-Expected Q1 Loss Apr 29 2016
Edited Transcript of ALKS earnings conference call or presentation 28-Apr-16 12:30pm GMT Apr 28 2016
Alkermes reports 1Q loss Apr 28 2016
Alkermes reports 1Q loss Apr 28 2016
Alkermes Announces Plan to Initiate Second Clinical Trial of ALKS 7119 Based on Preliminary Phase 1... Apr 28 2016
Alkermes plc Reports First Quarter 2016 Financial Results Apr 28 2016
Alkermes plc Reports First Quarter 2016 Financial Results Apr 28 2016
Alkermes Announces Plan to Initiate Second Clinical Trial of ALKS 7119 Based on Preliminary Phase 1... Apr 28 2016
Alkermes to Host Conference Call to Discuss First Quarter 2016 Financial Results Apr 21 2016
Alkermes to Host Conference Call to Discuss First Quarter 2016 Financial Results Apr 21 2016
Alkermes to Present Data on Schizophrenia Portfolio at Upcoming Schizophrenia International Research... Mar 28 2016
Alkermes to Present Data on Schizophrenia Portfolio at Upcoming Schizophrenia International Research... Mar 28 2016
Alkermes’ Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference Mar 09 2016
Alkermes reports 4Q loss Feb 25 2016
Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2015 and Provides Financial... Feb 25 2016
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2015 Financial Results Feb 18 2016
Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences Feb 02 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119 Jan 25 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119 Jan 25 2016
Alkermes Announces Topline Results of FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 in... Jan 21 2016
Alkermes Announces Topline Results of FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 in... Jan 21 2016
Alkermes’ Corporate Presentation to be Webcast at the 34th Annual J.P. Morgan Healthcare... Jan 05 2016
Alkermes’ Corporate Presentation to be Webcast at the 34th Annual J.P. Morgan Healthcare... Jan 05 2016
Alkermes Announces Achievement of Milestones for CNS Medicines in Proprietary Product and Pipeline... Dec 16 2015
Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2015 London Healthcare Conference Nov 11 2015
Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2015 London Healthcare Conference Nov 11 2015
Alkermes’ Corporate Presentation to Be Webcast at the Credit Suisse 24Th Annual Healthcare... Nov 03 2015
Alkermes’ Corporate Presentation to Be Webcast at the Credit Suisse 24Th Annual Healthcare... Nov 03 2015
Alkermes reports 3Q loss Oct 29 2015
Alkermes Announces Positive Clinical Trial Results and Streamlined Registration Pathway for ALKS... Oct 29 2015
Alkermes plc Reports Third Quarter 2015 Financial Results Oct 29 2015
Alkermes plc Reports Third Quarter 2015 Financial Results Oct 29 2015
Alkermes Announces Positive Clinical Trial Results and Streamlined Registration Pathway for ALKS... Oct 29 2015
Alkermes to Host Conference Call to Discuss Third Quarter 2015 Financial Results Oct 22 2015
Alkermes’ Corporate Presentation to Be Webcast at the Morgan Stanley Global Healthcare Conference Sep 10 2015
Alkermes Provides Update on FDA Review of ARISTADA™ for the Treatment of Schizophrenia Aug 21 2015
Alkermes reports 2Q loss Jul 30 2015
Alkermes plc Reports Second Quarter 2015 Financial Results Jul 30 2015
Alkermes to Host Conference Call to Discuss Second Quarter 2015 Financial Results Jul 23 2015
Alkermes reports 1Q loss Apr 30 2015
Alkermes beats Street 4Q forecasts Feb 24 2015
Alkermes reports 3Q loss Oct 29 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)